19/07/2019 04:47:19

Amarin Prices Public Offering of American Depositary Shares

BEDMINSTER, N.J. and DUBLIN, Ireland, July 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS. The gross proceeds of this offering are expected to be approximately $400.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin. The offering is expected to close on or about July 23, 2019, subject to customary closing conditions.

Amarin intends to use the net proceeds from the offering (1) to support the ongoing and expanding commercialization of Vascepa® (icosapent ethyl) assuming the FDA approves Amarin’s supplemental new drug application seeking an expanded indication for Vascepa in the United States based on the positive results of Amarin’s REDUCE-IT™ study, including (i) doubling the size of its existing sales force, (ii) increasing branded and non-branded advertising, and (iii) supporting its expanded commercial operations; (2) to increase commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes. Amarin also may use a portion of the net proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard.

In addition, Amarin has granted the underwriters a 30-day option to purchase up to an aggregate of 3,333,333 additional ADSs. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC and Roth Capital Partners are acting as the co-managers for the offering.

The securities described above are being offered by Amarin pursuant to a shelf registration statement on Form S-3ASR (No. 333-216385) previously filed with the Securities and Exchange Commission (the "SEC") on March 1, 2017 and automatically became effective upon filing. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at https://www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement relating to these securities may be obtained for free by visiting EDGAR on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or by telephone at (866) 803-9204; or by email at prospectus-eq_fi@jpmchase.com, Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: (877) 547-6340 or email: Prospectus_Department@jefferies.com or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; or by email at prospectus@cantor.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Amarin

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit www.amarincorp.com.

Disclosure Notice

This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements related to Amarin's public offering of American Depositary Shares and the FDA’s evaluation of Amarin’s pending supplemental new drug application, are forward-looking statements that involve risks and uncertainties. Words such as "intends," "plans," "expects," "may," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are not promises or guarantees. These forward-looking statements are based upon Amarin's current expectations. Actual events and results and the timing of events and results could differ materially from those anticipated in such forward-looking statements. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks related to the underwriters’ consummation of their obligation to purchase the securities, whether Amarin will be able to satisfy its obligations to close the offering and the risk that Amarin will not use the proceeds from the offering in the manner contemplated, as well as the risks, uncertainties and other matters detailed in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q and the preliminary prospectus supplement relating to the offering and filed on July 17, 2019. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by law.

Amarin contact information:

Investor Relations:

Elisabeth Schwartz

Investor Relations and Corporate Communications

Amarin Corporation plc

In U.S.: +1 (908) 719-1315

investor.relations@amarincorp.com

Lee M. Stern

Trout Group 

In U.S.: +1 (646) 378-2992

lstern@troutgroup.com

Media Inquiries:

Gwen Fisher

Corporate Communications

Amarin Corporation plc

In U.S.: +1 (908) 325-0735

pr@amarincorp.com

Amarin Corporation plc Logo

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
23 Aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
41
25 Aug
VELO
Det er interessant at kigge på Veloxis vækst og nuværende position i markedet for at regne frem til ..
38
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
21
22 Aug
 
Jeg synes hun gjorde det fremragende i sagen om Grønland og Trump.   Det vigtigste i en sådan situat..
20
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
24 Aug
GOMX
Har aktien:   GOMSPACE: TECKNAR AVTAL MED ESA VÄRT 1,4 MLN EUR 19:26STOCKHOLM (Nyhetsbyrån Direkt) R..
15
23 Aug
VELO
Netop i denne måned har jeg været på EuroInvestor i 1 år og manglede, for at sige det mildt, baggrun..
15
20 Aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15
23 Aug
PNDORA
@Fqvist1 - ser er du er short fra 257, jf. din orientering d. 20.08. Jeg vil gerne gentage udbygge m..
14

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Maha Energy AB (publ) (“Maha” or the “Company”) Announces Filing of Second Quarter Report and Live Webcast
2
Texas Clinic of Chiropractic Declares Its Grand Opening in New Braunfels, Texas
3
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Acer Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
4
PRF: Consolidated Unaudited Interim Report of AS PRFoods for the 4th quarter and 12 months of 2018/2019 financial year
5
WISeKey has submitted a confidential draft registration statement on Form 20-F under the US Securities Exchange Act of 1934 to the U.S. Securities and Exchange Commission (SEC)

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 August 2019 09:16:34
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-26 10:16:34 - 2019-08-26 09:16:34 - 1000 - Website: OKAY